This week
the skin cancer foundation warned against melanotan II on july 7 — and the viral tiktok that triggered it
On July 7, the Skin Cancer Foundation published a press release that used language rarely seen in foundation communications: *alarming*. The organization [warned the public against Melanotan II](https://www.skincancer.org/press/the-skin-cancer-foundation-issues-warning-regarding-melanotan-ii/) — an injectable, unregulated tanning peptide circulating widely on TikTok and wellness forums — citing skin cancer risks, uncontrolled melanin stimulation, and the absence of any regulatory oversight. Two days later, [ScienceAlert summarized what dermatologists were seeing](https://www.sciencealert.com/dermatologists-alarmed-by-concerning-injectable-tan-trend): patients walking into clinics with dramatically darkened skin, sometimes covering moles and melanomas that had been hiding in plain sight. The trend had accelerated through social media, where users filmed themselves injecting a peptide compound purchased from unregulated online vendors, captioning the results as "natural" or "healthy" tans. Melanotan II is not FDA-approved. It is not a pharmaceutical. It has no approved labeling, no standardized manufacturing process, and no safety data from controlled human trials. What it does have is a mechanism: it activates melanocortin receptors, the same biological pathway that the FDA has already approved — in a different, more selective drug — for a specific skin disease. That drug is afamelanotide. And understanding why it exists, and what it is actually approved for, is the fastest way to understand why the Melanotan II trend landed with such alarm this week.
The actual mechanism
melanotan II hits four receptor subtypes. afamelanotide targets one. that gap is the whole story.
The melanocortin system is a family of five receptors — MC1R through MC5R — distributed across the skin, brain, adrenal glands, and reproductive organs. Activate them selectively and you get specific effects. Activate them indiscriminately and you get a pharmacological whirlwind. Melanotan II, the unregulated compound, is a broad agonist. It binds MC1R (pigmentation), MC3R and MC4R (appetite, sexual function, cardiovascular regulation), and to some extent MC5R (exocrine glands). That breadth is why users report tanning — and also why they report nausea, spontaneous erections, facial flushing, and elevated blood pressure. The compound was originally synthesized as a research tool, not a therapeutic. It was never developed through clinical trials. It is a pharmacological blunderbuss. Afamelanotide is structurally related but selectively optimized. It is an alpha-melanocyte-stimulating hormone analog, primarily active at MC1R, the receptor on melanocytes responsible for melanin production. The selectivity is not perfect — no peptide in this class achieves pure MC1R specificity — but the therapeutic development process refined it toward the pigmentation pathway and away from the systemic effects that make Melanotan II dangerous. That selectivity is what made clinical trials possible. And those trials had a very specific target.
What people are claiming
tanning culture calls it 'a natural tan.' dermatologists call it 'a mole obscurer.'
The community framing of Melanotan II across social platforms has been remarkably consistent: it is described as a hack for achieving a "natural" complexion without sun exposure, a beauty shortcut with fewer UV risks than a tanning bed, and — in some corners — a legitimate biohacking protocol that simply has not been approved yet because of regulatory inertia. Dermatologists have a different read. When [a viral account described a weeks-long self-administration arc with MT-2 last week](https://www.thebiglead.com/man-takes-mt2-tan/), the medical community's concern was not primarily about the erratic dosing or the unknown compound purity. It was about the moles. Melanin stimulation at this scale and without clinical oversight does not discriminate between normal melanocytes and atypical ones. A peptide that darkens everything can make surveillance of existing nevi — and early-stage melanomas — significantly harder. This is the precise scenario the Skin Cancer Foundation highlighted: not just that Melanotan II is unregulated, but that its specific biological action can obscure the visual markers clinicians use to catch skin cancer early. None of this pharmacological reasoning gets much airtime in the TikTok discourse. What does circulate is before-and-after imagery, personal testimonials, and a confident community consensus that the product delivers what it promises. The mechanism, when it comes up at all, is described as an advantage.
What the data says
afamelanotide cleared phase 3. it is approved for erythropoietic protoporphyria. that is a very specific disease.
The FDA approved afamelanotide — branded as Scenesse — in 2019 for adults with erythropoietic protoporphyria (EPP), a rare genetic disorder in which a deficiency of the enzyme ferrochelatase leads to the accumulation of protoporphyrin IX in red blood cells. When those cells reach the skin and encounter light, the reaction is severely painful: burning, stinging, and in some cases, long-term skin damage. Patients with EPP are often unable to spend more than minutes in sunlight without debilitating pain. The clinical logic of afamelanotide for EPP is straightforward: by stimulating melanin production via MC1R, the drug increases the photoprotective pigment in the skin, extending the amount of time EPP patients can tolerate light exposure. Phase 3 trials demonstrated statistically significant improvement in pain-free light exposure time compared to placebo. That evidence — [catalogued in the DailyMed prescribing information](https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Afamelanotide) and summarized across multiple [clinical trial records at PubMed](https://pubmed.ncbi.nlm.nih.gov/?term=Afamelanotide) — is specific to EPP. The approval is not a green light for cosmetic use, recreational tanning, or any of the adjacent claims that circulate about melanocortin peptides in wellness contexts. It is a narrow, evidence-supported approval for a specific rare disease with a specific mechanism. Understanding that distinction is not a technicality. It is the point.
Approved — PeptideFactCheck stance
the fda approval means exactly what it says. nothing more, nothing less.
Afamelanotide sits in the PeptideFactCheck evidence tier marked "Approved" — the highest classification in the framework. That designation means the drug has regulatory approval for at least one specific use, supported by controlled clinical trial data and agency review. It does not mean approval is a blanket endorsement of every melanocortin claim circulating in wellness and biohacking spaces. The approval covers afamelanotide, for EPP, via the prescribed medical pathway. Full stop. The distinction matters this week because the compound generating the most social media attention — Melanotan II — shares a receptor class with afamelanotide but shares none of its regulatory history. The two are not interchangeable. Citing one to legitimize the other is a category error that the Skin Cancer Foundation, the dermatology community, and the basic structure of the FDA approval process all reject. What the existence of afamelanotide demonstrates is that the melanocortin pathway can be the basis of a real, approved medicine when the development pathway is followed: controlled trials, defined indication, risk evaluation, approved labeling. What Melanotan II demonstrates is what happens when that pathway is skipped. The Skin Cancer Foundation's warning this week is the predictable result of that skip.
Editorial boundary
What this page will not do
It will not provide dosing, cycling, sourcing, injection, or personal medical instructions. The job is to classify claims and explain mechanisms.